Tag - pharmaceuticals

 
 

PHARMACEUTICALS

Japan Times
BUSINESS / Markets
Jan 10, 2023
Eisai shares jump after FDA approves Alzheimer’s drug lecanemab
The drug, to be sold under the brand name Leqembi, was approved by the Food and Drug Administration under an accelerated pathway.
Japan Times
ASIA PACIFIC / Science & Health
Jan 7, 2023
China in talks with Pfizer for generic COVID drug
Beijing is in talks with the drugmaker to secure a license that will allow domestic firms to manufacture and distribute a generic version of its Paxlovid antiviral drug.
Japan Times
BUSINESS / Companies
Jan 6, 2023
Shionogi's COVID-19 pill may get China approval in March
The Japanese drugmaker has been submitting data to regulators in China and expects Xocova to be authorized for use as early as this quarter, Chief Executive Officer Isao Teshirogi said.
Japan Times
COMMENTARY / World
Jan 4, 2023
Cancer vaccine hunt finally makes progress
A small study shows promise in deploying mRNA technology against melanoma — but fighting tumors is vastly more complex than tackling COVID-19.
Japan Times
ASIA PACIFIC
Dec 30, 2022
China's COVID wave sparks scramble for vital drugs across Asia
Beijing's decision to abruptly remove most pandemic restrictions with little preparation is driving an unprecedented number of cases, leaving hospitals and funeral homes overwhelmed.
Japan Times
BUSINESS / Companies
Dec 28, 2022
Tokyo firm targets blood tests for Alzheimer's in wake of therapy breakthrough
Fujirebio Holding is boosting its lineup of reagents used to detect Alzheimer's biomarkers in blood tests.
Japan Times
JAPAN / Science & Health
Dec 22, 2022
Japan approves blood test to detect Alzheimer’s
Japan has approved one of the world’s first blood test kits to detect signs of Alzheimer’s disease, paving way for a simpler and speedier diagnosis of the ailment for which a therapy is on the horizon.
Japan Times
WORLD / Science & Health
Dec 22, 2022
Injectable HIV treatment offers hope to Ugandan patients
Some hope the new treatment option could help to reduce the stigma HIV patients suffer, particularly gay men.
Japan Times
BUSINESS / Companies
Dec 14, 2022
Takeda to pay up to $6 billion for Nimbus immune-therapy drug
After an initial $4 billion payment upfront, U.S.-based Nimbus is eligible for two additional $1 billion payments based on sales.
Japan Times
JAPAN / Science & Health
Dec 13, 2022
Shionogi says Japan government to buy 1 million more COVID pill doses
The added supply agreement comes at a time when Japan is dealing with an eighth wave of COVID-19 infections.
Japan Times
BUSINESS
Nov 30, 2022
Eisai Alzheimer’s drug sparks debate over benefits as risks like brain bleeding emerge
The key issue is whether the modest slowing of the disease is meaningful to individual patients and their families, especially in light of the potential side effects.
Japan Times
BUSINESS / Markets
Nov 29, 2022
Eisai and Biogen plunge after report of second death in Alzheimer’s trial
The case involved a 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, a report said.
Japan Times
WORLD / Science & Health
Nov 25, 2022
Researchers test mRNA technology for universal flu vaccine
A universal vaccine would not mean an end to flu seasons, but would replace the guess work that goes into developing annual shots months ahead of flu season each year.
Japan Times
JAPAN / Science & Health
Nov 15, 2022
Japan's Daiichi Sankyo says mRNA COVID vaccine successful in booster trial
Approval would give Japan a home-grown source for mRNA vaccines, which have made up the bulk of its COVID-19 inoculations to date.
Japan Times
BUSINESS / Companies
Oct 26, 2022
Lotte made its name in candy. Now it’s moving into drugmaking.
The new direction comes after a number of prominent South Korean family-run businesses turned to the highly profitable $1.3 trillion global biopharma business.
Japan Times
WORLD
Oct 26, 2022
New COVID boosters aren’t better than old ones, small study finds
The early results don't mean that getting a bivalent shot has no benefit, but they do raise the question of whether the switch to a new version of the vaccine was necessary.

Longform

Construction takes place on the Takanawa Gateway Convention Center in Tokyo, slated to open in 2025.
A boom for business tourism in Japan?